RIVM will calculate temporary background value for PFAS in soil In the coming weeks, RIVM will derive a temporary background value for PFAS in Dutch soil. This will be done based on measurement data from the provinces in the Netherlands.
RIVM reaction to farmers protest on 16 October 2019 On 16 October, farmers protested in the vicinity of RIVM in Bilthoven. The Director-General of RIVM, Hans Brug, was present at the protest site.
Openness about nitrogen There is concern about the current approach to nitrogen and the proposed measures; these concerns have been expressed in Dutch society as a whole and amongst farmers in particular.
Cold meat cuts probable source of 20 listeria cases RIVM has identified a cluster of 20 patients diagnosed with listeria over the past 2 years who are most likely to have been infected with an identical strain.
Application of personalised medicine: opportunities and challenges Pharmacotherapy based on individual patient characteristics such as genetic makeup, offers many potential benefits towards more effective treatment of a patients’ disease.
Strict diet combats aging diseases Mice with a severe aging disease live three times longer if they eat thirty percent less. Moreover, they age much healthier than mice that eat as much as they want.
Improved protection against pertussis The international PERISCOPE project has been granted a 30 million Euro European subsidy in order to better map the immune response to pertussis infection and vaccination.
Mental care still the most expensive of all In 2011, 19.6 billion euros was spent on the treatment of mental disorders. This amounted to 22% of the total expenditure on health and welfare during that year.
Risks of eHealth technology RIVM and Nictiz have made an overview of the risks that eHealth applications may entail and how these risks can be controlled.
Key organisations unite to improve benefit and risk assessments of vaccines Leading organisations have joined forces to launch a unique project that will pave the way for a pan-European framework for rapidly assessing and communicating the benefits and risks of vaccines.